Literature DB >> 656292

Identification of hydrallazine and hydrallazine hydrazone metabolites in human body fluids and quantitative in vitro comparisons of their smooth muscle relaxant activity.

K D Haegele, A J McLean, P du Souich, K Barron, J Laquer, J L McNay, O Carrier.   

Abstract

1 Serum and urine from hypertensive subjects on chronic oral hydrallazine therapy were studied using gas chromatographic/mass spectrometry techniques. 2 Metabolites resulting from acetylation, hydrolysis and conjugation reactions were detected. The acetone, pyruvate and alpha-ketoglutarate hydrazone were identified. 3 The activity of the pyruvate and alpha-ketoglutarate hydrazones were compared with that of hydrallazine using isolated rabbit aortic strips. 4 Both hydrazones were active under in vitro conditions, producing smooth muscle relaxant effects equal to those of hydrallazine. 5 It is concluded that hydrazone metabolites will contribute to the hypotensive effects of hydrallazine therapy in proportion to their relative abundance, persistence in vascular tissues and intrinsic activity.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 656292      PMCID: PMC1429372          DOI: 10.1111/j.1365-2125.1978.tb01662.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  THE METABOLISM OF 1-HYDRAZINOPHTHALAZINE.

Authors:  W M MCISAAC; M KANDA
Journal:  J Pharmacol Exp Ther       Date:  1964-01       Impact factor: 4.030

2.  Hypotensive hydrazinophthalazines and related compounds.

Authors:  J DRUEY; A MARXER
Journal:  J Med Pharm Chem       Date:  1959-02

3.  Determination of hydralazine and its metabolites by gas chromatography-mass spectrometry.

Authors:  K D Haegele; H B Skrdlant; N W Robie; D Lalka; J L McNay
Journal:  J Chromatogr       Date:  1976-11-03

Review 4.  Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis.

Authors:  H M Perry
Journal:  Am J Med       Date:  1973-01       Impact factor: 4.965

5.  Plasma levels of real and "apparent" hydralazine in man and rat.

Authors:  S B Zak; G Lukas; T G Gilleran
Journal:  Drug Metab Dispos       Date:  1977 Mar-Apr       Impact factor: 3.922

6.  Studies on hydralazine. II. Elimination rate and steady-state concentration in patients with impaired renal function.

Authors:  T Talseth
Journal:  Eur J Clin Pharmacol       Date:  1976-09-30       Impact factor: 2.953

7.  Comparative evaluation of the in vitro effects of hydralazine and hydralazine acetonide on arterial smooth muscle.

Authors:  K Barron; O Carrier; K D Haegele; A J McLean; J L McNay; P Du Souich
Journal:  Br J Pharmacol       Date:  1977-11       Impact factor: 8.739

8.  Physiological disposition of hydralazine (1-hydrazinophthalazine) and a method for its determination in biological fluids.

Authors:  A R SCHULERT
Journal:  Arch Int Pharmacodyn Ther       Date:  1961-06-01
  8 in total
  3 in total

Review 1.  Clinical pharmacokinetics of hydralazine.

Authors:  T M Ludden; J L McNay; A M Shepherd; M S Lin
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

2.  Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.

Authors:  D D Shen; J P Hosler; R L Schroder; D L Azarnoff
Journal:  J Pharmacokinet Biopharm       Date:  1980-02

3.  Effect of food on the absorption of hydralazine in man.

Authors:  R J Walden; R Hernandez; D Witts; B R Graham; B N Prichard
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.